ArticleDrug and alcohol review2025
The prevalence and correlates of self-reported cannabis use for medicinal, dual and recreational motives in Australia: Findings from the National Drug Strategy Household Survey 2022/2023.
Article in Drug and alcohol review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Doubtful medical cannabis prescribing practices identified from 55 medical cannabis websites.The Australian and New Zealand journal of psychiatry · 2026Article
- The prevalence and correlates of self-reported cannabis use for medicinal, dual and recreational motives in Australia: Findings from the National Drug Strategy Household Survey 2022/2023.Drug and alcohol review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCannabis has been prescribed as a medicine in Australia since 2016. The current study aimed to conduct a descriptive, epidemiological investigation on the prevalence and correlates of cannabis use for different motives (recreational-only, medical-only or dual-use) in Australia. It also aimed to examine the correlates of different cannabis use motives.
methodsThe National Drug Strategy Household Survey 2022/2023 was used to estimate the prevalence and correlates of cannabis use motives among Australians. Prevalence estimates were weighted to the population and multinomial logistic regressions were used to examine the impact of age, gender, frequency of use and some of the most common conditions for which cannabis is prescribed in Australia (i.e., chronic pain, cancer and anxiety) on cannabis use motives.
resultsThe prevalence of medical-only cannabis use was 1.0% (95% confidence interval [CI] 0.6, 1.4%), recreational-only use was 8.6% (CI 7.5, 9.7%) and dual-use was 1.9% (CI 1.3, 2.5%). Respondents who reported chronic pain had a stronger association with medical-only (relative risk ratio [RRR] = 8.10, p < 0.001) or dual-use motives (RRR = 5.17, p < 0.001) compared to recreational-only. Respondents who usually obtained cannabis via prescription had a stronger association with medical-only motives compared to dual-use (RRR = 10.55, p < 0.001). Greater frequency of use was more strongly associated with dual-use motives compared to recreational-only. DISCUSSION AND
conclusionsThe emergence of dual-use cannabis consumers is a conundrum for the current medicinal cannabis policy framework in Australia. Research on the potential harms associated with the dual-use and medical-only use of cannabis should be prioritised as prescriptions for medicinal cannabis increase and barriers to access are lessened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.